INTRODUCTION {#s1}
============

Reticular dysgenesis (MIM 267500) is one of the rarest and most severe forms of SCID. It is characterized by the combination of SCID with congenital agranulocytosis and bilateral sensorineural deafness. Impairment in lymphoid and myeloid lineages results in profound neutropenia (unresponsive to granulocyte colony stimulating factor; GCSF) along with T and natural killer (NK) cell lymphopenia in affected patients ([@MCS005017ICHC8]). Like other forms of SCID, treatment is with hematopoietic stem cell transplant.

Reticular dysgenesis is an autosomal recessive disorder caused by biallelic loss-of-function pathogenic variants in *AK2* (MIM 103020) ([@MCS005017ICHC8]; [@MCS005017ICHC10]). *AK2* encodes adenylate kinase 2, an enzyme in the mitochondrial intermembrane space that catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. AK2 deficiency significantly impairs energy metabolism, leading to reduced hematopoietic stem, and progenitor cells ([@MCS005017ICHC5]).

Two intronic *AK2* mutations, affecting canonical splice sites, have previously been reported in patients with reticular dysgenesis ([@MCS005017ICHC10]). Non-canonical splice site variants may also be predicted to affect splicing by in silico tools, although these variants often lack direct evidence and remain variants of unknown significance (VUS). RNA analysis has the potential to resolve these as abnormal RNA transcripts can be considered a very strong line of evidence supporting pathogenicity ([@MCS005017ICHC13]). Here we report the first non-canonical splice site pathogenic variant in *AK2*, resulting in reticular dysgenesis in the homozygous state.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

This male patient of Sudanese ancestry with consanguineous parents presented to our Pediatric Clinical Genetics Service at 28 d of life (DOL) due to a positive NBS for SCID (\<200 TRECS/µl blood) and follow-up testing consistent with SCID.

He was born full-term following an uncomplicated pregnancy and admitted to the NICU for respiratory distress. He was found to have severe neutropenia on DOL 1, which persisted despite receiving GCSF. On DOL 7, he had an episode of severe metabolic acidosis, and complete metabolic work-up was unremarkable.

Further evaluation demonstrated CD3 T cells of 37 cells/mcL (reference range 769--2222), CD4 T cells of 31 cells/mcL (429--1131), CD4+45RA+ cells of 0 cells/mcL (89--789), CD8 T cells of 6 cells/mcL (209--768), CD19 B cells of 95 cells/mcL (85--441), NK cells of 62 cells/mcL (78--510), NK function of 4% cytotoxicity (17--78), phytohemagglutinin (PHA) of 59% of CD3 (77--100), IgA \< 5 mg/dL (3--30), and IgM \< 5 mg/dL (10--90). There was no evidence of maternal engraftment revealed by testing of short tandem repeats within the T cell subset.

Other clinical features included small ventriculoseptal defects, an anorectal malformation with excessive perianal tissue, and short stature (tracking at or below third percentile for height). He passed his hearing newborn screening (NBS); however, a follow-up hearing evaluation was performed because of clinical concerns, and an auditory brainstem response revealed profound bilateral sensorineural hearing loss.

Initial genetic testing at GeneDx (Gaithersburg, MD) included a karyotype, which was normal, and a chromosome microarray, which detected regions of homozygosity consistent with reported consanguinity but no deletions or duplications. An 85-gene Comprehensive SCID and CID Panel (Invitae) revealed two homozygous and three heterozygous VUS, all in genes associated with autosomal recessive forms of immunodeficiency. The homozygous variants were *AK2* c.330 + 5G \> A and *ATM* (MIM 607585) c.5497 − 4C \> G. Alpha-fetoprotein (AFP) levels were normal for age and downtrending, so the *ATM* variant was considered not clinically significant. The *AK2* variant in intron 3 was suspicious, although at this time remained a VUS. The parents were both heterozygous for the *AK2* variant. Given the patient\'s additional clinical features and known consanguinity, exome sequencing was subsequently sent to GeneDx and revealed an additional diagnosis of Stickler syndrome type V (MIM 614284) because of a homozygous *COL9A2* (MIM 120260) likely pathogenic variant (c.1242delC; p.G415Efs\*116). Details of the three variants are provided in [Table 1](#MCS005017ICHTB1){ref-type="table"}.

###### 

Variants described in this patient

  Gene       Chromosome   HGVS DNA reference             HGVS protein reference       Variant type   Predicted effect   dbSNP          Genotype     Comments
  ---------- ------------ ------------------------------ ---------------------------- -------------- ------------------ -------------- ------------ ------------
  *AK2*      1            NM_001625.3: c.330 + 5G \> A                                SNV            Splicing defect                   Homozygous   
  *ATM*      11           NM_000051.3: c.5497-4C \> G                                 SNV            Unknown            rs1002998981   Homozygous   Normal AFP
  *COL9A2*   1            NM_001852.3:c.1242delC         NP_001843.1:p.G415Efs\*116   Deletion       Frameshift         rs756694568    Homozygous   

(SNV) Single-nucleotide variant, (AFP) alpha-fetoprotein.

At 3 mo old, the patient underwent peripheral blood stem cell transplant from a matched unrelated donor following cytoreduction with busulfan, fludarabine, and rabbit antithymocyte globulin (rATG) and engrafted.

RNA-seq Analysis {#s2b}
----------------

In silico analyses had predicted that *AK2* c.330 + 5G \> A likely weakens the native donor site ([Table 2](#MCS005017ICHTB2){ref-type="table"}). To directly determine the impact on splicing, we analyzed RNA from the proband and his unaffected parents. Electrophoresis of reverse transcriptase-polymerase chain reaction (RT-PCR) products showed that the proband lacks the normal transcript, whereas the parents have similar amounts of normal and truncated transcripts ([Fig. 1](#MCS005017ICHF1){ref-type="fig"}A). Quantitation of RNA-seq results revealed that this variant results in near complete skipping of exon 3 (r.220_330del) in the proband and ∼50% skipping in his parents ([Fig. 1](#MCS005017ICHF1){ref-type="fig"}B,C). The loss of exon 3 is predicted to result in an in-frame deletion of 37 amino acids, which account for 15% (37/239 amino acids) of the AK2 protein. The proband also had small amounts of transcripts missing exons 2 and 3 (r.94_330del), which were absent in other samples (data not shown).

![Aberrant splicing caused by *AK2* c.330 + 5G \> A. (*A*) TapeStation electrophoresis of reverse transcriptase-polymerase chain reaction (RT-PCR) products with the schematic of predicted mRNA. Locations of the primers are shown by arrows. (C1 and C2) Negative controls (blood), (C3) negative control (colon), (NTC) no template control, (MW) molecular weight. (*B*) Sashimi plot of *AK2* exons 2--4 from CloneSeq, showing that the majority of reads in the proband do not harbor exon 3. RefSeq *AK2* isoform (NM_001625) is shown at the *bottom*. (*C*) Relative quantification of abnormal transcripts shown in *B*: r.220_330del (skipping of exon 3). (PSI) Percent spliced in index.](MCS005017Ich_F1){#MCS005017ICHF1}

###### 

In silico analyses of *AK2* c.330 + 5G \> A

  Prediction tool                             Reference (G) score   Variant (A) score   Variation (%)
  ------------------------------------------- --------------------- ------------------- ---------------
  NNSplice ([@MCS005017ICHC12])               0.43                  0.03                −93.02
  ESEfinder ([@MCS005017ICHC2])               9.17                  5.73                −37.51
  Human Splicing Finder ([@MCS005017ICHC3])   84.80                 72.63               −14.35
  MaxEnt ([@MCS005017ICHC16])                 6.18                  −1.33               −121.52
  SpliceAI ([@MCS005017ICHC6])                N/A                   DL 0.91^a^          N/A

^a^Probability of donor site loss.

Variant Reclassification {#s2c}
------------------------

Variant classification was then revisited. Final classification was made based on our internal variant assessment scheme, as well as ACMG guidelines, which apply evidence based on the type and strength of the criteria for pathogenicity---Pathogenic Supporting (PP), Pathogenic Moderate (PM), Pathogenic Strong (PS), and Pathogenic Very Strong (PVS) ([@MCS005017ICHC13]). This variant is absent in gnomAD (PM2), and all in silico tools predict weakening of the native donor site (PP3). The phenotype was consistent with reticular dysgenesis (PP4_Moderate).

RNA results could be considered strong evidence (PS3) per ACMG guidelines. However, because they provided exact molecular consequence of this variant (exon 3 skipping), we used recommended PVS1 criterion for deletion of an exon ([@MCS005017ICHC1]). The deleted region (p.V74_M110del) located in the adenylate kinase domain ([@MCS005017ICHC8]) is likely critical for catalytic activity. The presence of exon 3 in almost all known alternate isoforms suggests that the region encoded by this exon is functionally important. One affected patient has been reported with a pathogenic missense variant in this region (p.Arg103Trp) that resulted in markedly lower levels of AK2 protein ([@MCS005017ICHC8]). Although the deletion likely impacts critical function of the protein, residual protein function cannot be ruled out because the deletion is in-frame. Thus, PVS1_Strong was assigned to the RNA evidence. With this evidence, the variant was reclassified to pathogenic based on our classification scheme or likely pathogenic by ACMG---one strong, two moderate, and one supporting.

DISCUSSION {#s3}
==========

Noncanonical splice site variants present a challenge for interpretation and often remain as unresolved VUS. In silico tools have limited ability to accurately predict effects on splicing. As presented here, RNA-seq provides an ideal platform for qualitative and quantitative assessment of intronic VUS, which can lead to reclassification if a significant impact on mRNA (or lack thereof) is observed. The RNA analysis we performed on *AK2* c.330 + 5G \> A revealed that this variant results in almost complete absence of normal transcripts, leading to its reclassification as (likely) pathogenic. Most importantly, this reclassification allowed us to provide a definitive diagnosis to the family.

One limitation of performing RNA-based analysis in many cases is the procurement of tissues that express the gene of interest. Many genes have little to no expression in blood or other readily available tissues. Being involved in early hematopoietic stem cell survival and function ([@MCS005017ICHC5]), *AK2* is highly expressed in hematopoietic tissue, allowing us to collect samples needed for the study. This and other genetic disorders of hematopoiesis and immunity may represent one of the more fruitful areas to apply RNA-based analysis for variant interpretation given the high gene expression in blood.

In addition to a unique hematological phenotype, reticular dysgenesis is associated with sensorineural hearing loss. Although Stickler syndrome likely also contributes to our patient\'s hearing loss, his profound hearing loss across all frequencies tested is beyond what would be expected because of Stickler syndrome alone, which results in high-frequency loss ([@MCS005017ICHC9]). Lactic acidosis has not been previously described as a manifestation of reticular dysgenesis; however, given AK2\'s role in metabolism and lactate production ([@MCS005017ICHC15]), it is possible that our patient\'s lactic acidosis was secondary to AK2 deficiency as opposed to an occult infection.

Amended results were provided to the family following transplant. In addition to providing a definitive diagnosis, the pathogenic result can be used for testing of siblings in the future. Reticular dysgenesis has specific implications for conditioning prior to stem cell transplant ([@MCS005017ICHC5]), and therefore making this diagnosis very early in life will be important for management of any future siblings or other relatives who may share the homozygous *AK2* variant.

In summary, we identified the first pathogenic noncanonical splicing variant in *AK2* in a patient with reticular dysgenesis. This highlights the utility and importance of RNA-based analysis for splicing.

METHODS {#s4}
=======

Massively Parallel RNA-seq Analysis {#s4a}
-----------------------------------

Peripheral blood samples were collected from the proband (prior to transplant) and his parents in PAXgene Blood RNA Tubes (QIAGEN). RNA isolation was performed on the QIAcube (QIAGEN) using the PAXgene Blood RNA Kit (PreAnalytiX). Massively parallel RNA-seq of cloned RT-PCR products (CloneSeq) was performed as described previously ([@MCS005017ICHC4]). Briefly, 300 ng of total RNA input was used to generate cDNA using the SuperScript IV kit and Oligo(dT) (QIAGEN). Primers spanning introns were custom designed: 5′-CGAACTGGTGGCAGTGAGA-3′ in exon 1 and 5′-GTTCCCCGGTGATGTCAT-3′ in exons 5/6 ([Figure 1](#MCS005017ICHF1){ref-type="fig"}A). Three independent RT-PCRs performed in proband, parents, and healthy blood and colon controls were pooled together, and size was determined using TapeStation D1000 reagents (Agilent). RT-PCR products were cloned using the pGEM-T Easy kit (Promega), and isolated plasmids underwent library prep using standard illumina dual index adapters. Paired-end sequencing was performed on MiSeq (illumina) using 250-bp reads.

Bioinformatics Analysis {#s4b}
-----------------------

Paired-end reads were aligned to the human genome (GrCh37/hg19) using STAR aligner v2.5.2a. Aligned reads were analyzed using a custom bioinformatics pipeline capable of detecting exon skipping, partial exon skipping, partial intron inclusion, intron retention, and the presence of a cryptic exon as described previously ([@MCS005017ICHC4]). The percentage of alternative splicing events was calculated relative to the primary *AK2* isoform (NM_001625) by dividing the number of reads supporting the splicing event by the total number of reads in the region of the splicing event. These values were normalized according to read length and exon length to determine percent spliced in (PSI) as described previously ([@MCS005017ICHC14]). Sashimi plots depicting the total reads spanning exons 2 to 5 were generated using Mixture of Isoforms software (MISO). Sashimi plots provide a quantitative visualization of aligned CloneSeq reads, enabling quantitative comparison of exon usage across samples ([@MCS005017ICHC7]).

Variant Classification {#s4c}
----------------------

Pathogenicity of the *AK2* variant was reassessed to incorporate RNA results. Classification is according to the classification scheme established by our laboratory ([@MCS005017ICHC11]), which incorporates ACMG guidelines ([@MCS005017ICHC13]) and was updated with recommended use of PVS1 criterion for loss-of-function variants ([@MCS005017ICHC1]). As a comparison, the variant was also reassessed using the ACMG guidelines.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The AK2 variant and our interpretation have been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV001244679. RNA sequence data that support the findings of this study are available on request from the corresponding author (E.F.). The patient data are not publicly available because they contain information that could compromise research participant privacy/consent.
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